Arch Scientists Successfully Image Brain Tumour Initiating Cells Using MRI
TORONTO, ONTARIO--(Marketwire - Aug. 21, 2012) - Arch Biopartners Inc ("Arch") (CNSX:ACH)(OTCBB:FOIFF) today announced Arch scientists have successfully used magnetic resonance imaging ("MRI") to detect human brain tumour initiating cells in mice using Arch's proprietary cell targeting technology.
Arch Awarded Funding from the Government of Canada to Develop Brain Tumour Targeting Technology
TORONTO, CANADA--(Marketwire - March 15, 2012) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) today announced that the National Research Council of Canada - Industrial Research Assistance Program (NRC-IRAP) has approved funding up to $107,000 to assist Arch in the development of diagnostic imaging applications for its brain tumour initiating cell ("BTIC") targeting technology.
Arch Scientists to Lead Anti Corrosion Project for Auto Industry
TORONTO, ONTARIO--(Marketwire - Feb. 28, 2012) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) today announced that AUTO21 and its contributing partners have approved funding totaling $518,400 for Arch scientists to lead an anti corrosion project on Magnesium ("Mg") and rare earth ("RE") alloys for the Canadian auto industry.